Cefixime 200mg tablets
Prescription only
Requires a prescription from a doctor or prescriber
Tablet
200mg
Oral
Antibacterial drugs
Active ingredients:
Cefixime
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Source: MHRA Products DatabaseOGL 3.0
Updated 3 months ago(16 Jan 2026)Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Cefixime
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Cefixime
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Show details
1 products
MHRA licensed products
View all licensed products for Cefixime on the MHRA register
Suprax 200mg tablets
Show details
£13.23indicative price
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
400 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Show details
Cefotaxime 1g/50ml infusion bags
Infusion
1g/50ml
Same therapeutic group
Cefotaxime 2g/100ml infusion bags
Infusion
2g/100ml
Same therapeutic group
Ceftazidime 2mg/0.1ml solution for injection pre-filled syringes
Injection
2mg/0.1ml
Same therapeutic group
Cefixime 400mg tablets
Tablet
400mg
Same therapeutic group
Ceftazidime 2g / Avibactam 500mg powder for solution for infusion vials
Infusion
2g
Same therapeutic group
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Cefixime
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3 to 4 hours
Mechanism
The bacterial cell wall, which is located at the periphery of Gram-positive bact…
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
40%
With oral administration of cefixime, about 40%-50% is absorbed whether administered with or without food.
[L49293]…
[L49293]…
Half-life
3 to 4 hours
Cefixime has a serum half-life averaging 3 to 4 hours in healthy subjects and is independent of dosage form.
[A262934][L49293]…
[A262934][L49293]…
Protein binding
65%
Approximately 65% of cefixime is bound to serum protein, the serum protein binding is also concentration-independent.
[L49293]
[L49293]
Volume of distribution
0.1 L/kg
Cefixime has a volume of distribution averaging 0.1 L/kg of body weight when administered orally.
[A262939]
[A262939]
Metabolism
There is no evidence of metabolism of cefixime in vivo.
[L49293]
[L49293]
Elimination
50%
Approximately 50% of absorbed cefixime is excreted unchanged in the urine in 24 hours.
[L49293]
[L49293]
Clearance
8 mg/k
Cefixime administered as an oral suspension with a dose of 8 mg/kg in children with urinary tract infections aged from 6 to 13 years resulted in a mean apparent total clearance rate of 4.74…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Investigational
Small molecule
About this compound
Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs).[A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death.[A232920][A232925][A232930] Cefixime is a broad-spectrum antibiotic and an orally-active third-generation semisynthetic cephalosporin.[A262894,A263011 ,L49293] Cephalosporins are beta-lactam antibiotics and can be used to treat gram-positive and gram-negative bacterial infections which include conditions such as skin infections, resistant bacteria, and meningitis.[A262995] Examples of third-generation cephalosporins are [ceftriaxone], [cefotaxime], and [ceftazidime].[A262995]
Third-generation cephalosporins are often a first-line therapy against certain bacterial infections.[A263026] However, cefixime is not recommended as a first-line of treatment for uncomplicated urogenital, anorectal, or pharyngeal gonorrhea because cefixime does not provide the same bactericidal effect as [ceftriaxone].[L49686][A263021] Generally, cefixime is used to treat uurinary tract infections, middle ear infections, pharyngitis, tonsillitis, exacerbations of chronic bronchitis, and uncomplicated gonorrhea.[L49293] The beta-lactam ring of cefixime inhibits bacterial cell wall synthesis by binding to the penicillin-binding proteins which will then result in lysis.[A262995][A262945][A262950] Specifically, cephalosporins inhibit penicillin-sensitive enzymes responsible for the final 3D structure of the bacterial cell wall which in turn inhibit bacterial cell wall peptidoglycan synthesis.[T894, T322] Additionally, third-generation cephalosporins have been shown to have more stability in the presence of beta-lactamases compared to first- and second-generation cephalosporins.[A263031] Cefixime was first approved in the United States in 1986.[L49293]
Third-generation cephalosporins are often a first-line therapy against certain bacterial infections.[A263026] However, cefixime is not recommended as a first-line of treatment for uncomplicated urogenital, anorectal, or pharyngeal gonorrhea because cefixime does not provide the same bactericidal effect as [ceftriaxone].[L49686][A263021] Generally, cefixime is used to treat uurinary tract infections, middle ear infections, pharyngitis, tonsillitis, exacerbations of chronic bronchitis, and uncomplicated gonorrhea.[L49293] The beta-lactam ring of cefixime inhibits bacterial cell wall synthesis by binding to the penicillin-binding proteins which will then result in lysis.[A262995][A262945][A262950] Specifically, cephalosporins inhibit penicillin-sensitive enzymes responsible for the final 3D structure of the bacterial cell wall which in turn inhibit bacterial cell wall peptidoglycan synthesis.[T894, T322] Additionally, third-generation cephalosporins have been shown to have more stability in the presence of beta-lactamases compared to first- and second-generation cephalosporins.[A263031] Cefixime was first approved in the United States in 1986.[L49293]
Properties:
solid
Avg. mass: 453.45 Da
DrugBank indication
Cefixime is indicated for the treatment of uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes, pharyngitis and tonsillitis caused by Streptococcus pyogenes, acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae, and uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase-and non-penicillinase-producing isolates).
[L49293]
[L49293]
Also known as(71)
(−)-cefixim
Cefixim
Cefixima
Céfixime
Cefixime
Cefixime anhydrous
Cefiximum
3.4.16.4
Dosage forms(80)
Capsule (Oral) — 400.000 mg
Tablet (Oral) — 400 mg
Tablet (Oral) — 400.00 mg
Capsule (Oral) — 200.000 mg
Suspension (Oral) — 2.000 g
Capsule (Oral) — 200 mg
Suspension (Oral) — 2.000 g
Capsule (Oral) — 223.83 MG
Molecular properties(19)
Drug interactions(128)
Known interactions with other medications. Always consult a healthcare professional.
Probenecid
Unknown severity
The serum concentration of Cefixime can be increased when it is combined with Probenecid.
Picosulfuric acid
Moderate
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefixime.
BCG vaccine
Moderate
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cefixime.
Typhoid vaccine
Moderate
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cefixime.
Dicoumarol
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Dicoumarol.
Phenindione
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Phenindione.
The therapeutic efficacy of Warfarin can be decreased when used in combination with Cefixime.
Phenprocoumon
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Phenprocoumon.
Acenocoumarol
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Acenocoumarol.
4-hydroxycoumarin
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with 4-hydroxycoumarin.
The risk or severity of bleeding can be increased when Cefixime is combined with Coumarin.
(R)-warfarin
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with (R)-warfarin.
Ethyl biscoumacetate
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Ethyl biscoumacetate.
Fluindione
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Fluindione.
Clorindione
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Clorindione.
Diphenadione
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Diphenadione.
Tioclomarol
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with Tioclomarol.
(S)-Warfarin
Unknown severity
The risk or severity of bleeding can be increased when Cefixime is combined with (S)-Warfarin.
The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefixime.
Bivalirudin
Moderate
The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefixime.
Anistreplase
Moderate
The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefixime.
Tenecteplase
Moderate
The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefixime.
Drotrecogin alfa
Moderate
The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefixime.
Streptokinase
Moderate
The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefixime.
Argatroban
Moderate
The therapeutic efficacy of Argatroban can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Ardeparin can be decreased when used in combination with Cefixime.
Fondaparinux
Moderate
The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Cefixime.
Pentosan polysulfate
Moderate
The therapeutic efficacy of Pentosan polysulfate can be decreased when used in combination with Cefixime.
Dipyridamole
Moderate
The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Heparin can be decreased when used in combination with Cefixime.
Enoxaparin
Moderate
The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Cefixime.
Epoprostenol
Moderate
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Cefixime.
Ximelagatran
Moderate
The therapeutic efficacy of Ximelagatran can be decreased when used in combination with Cefixime.
Desmoteplase
Moderate
The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Cefixime.
Defibrotide
Moderate
The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Ancrod can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Beraprost can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Prasugrel can be decreased when used in combination with Cefixime.
Rivaroxaban
Moderate
The therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Cefixime.
Sulodexide
Moderate
The therapeutic efficacy of Sulodexide can be decreased when used in combination with Cefixime.
Semuloparin
Moderate
The therapeutic efficacy of Semuloparin can be decreased when used in combination with Cefixime.
Idraparinux
Moderate
The therapeutic efficacy of Idraparinux can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Cangrelor can be decreased when used in combination with Cefixime.
Astaxanthin
Moderate
The therapeutic efficacy of Astaxanthin can be decreased when used in combination with Cefixime.
The therapeutic efficacy of Apixaban can be decreased when used in combination with Cefixime.
Otamixaban
Moderate
The therapeutic efficacy of Otamixaban can be decreased when used in combination with Cefixime.
Showing 50 of 128 interactions
Food & lifestyle interactions
Advice
Take with or without food. The capsule and tablet may be administered without regard to food. However, the time to maximal absorption is increased approximately 0.8 hours when administered with food while taking with food reduces the absorption following administration of the capsule by approximately 15% based on AUC and 25% based on Cmax.
Toxicity & overdose
Toxicity information specific to cefixime is not conclusive. Symptoms of overdose can include severe vomiting and seizures.
[L49419]
As cefixime is a cephalosporin, it may trigger seizures, particularly in patients with renal impairment when the dosage was not reduced.
[L49293]
Additionally, patients experiencing an overdose are at an increased risk of severe adverse effects such as diarrhea, nausea, loose stools, abdominal pain, dyspepsia, and vomiting.
[L49293]
In case of overdose, no specific antidote exists and this drug is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis; however, gastric lavage may be indicated.
[L49293]
Symptomatic and supportive measures are recommended.
Animal studies revealed an oral LD50 greater than 10g/kg in rats.
[L49545]
[L49419]
As cefixime is a cephalosporin, it may trigger seizures, particularly in patients with renal impairment when the dosage was not reduced.
[L49293]
Additionally, patients experiencing an overdose are at an increased risk of severe adverse effects such as diarrhea, nausea, loose stools, abdominal pain, dyspepsia, and vomiting.
[L49293]
In case of overdose, no specific antidote exists and this drug is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis; however, gastric lavage may be indicated.
[L49293]
Symptomatic and supportive measures are recommended.
Animal studies revealed an oral LD50 greater than 10g/kg in rats.
[L49545]
How it works
Mechanism of action
The bacterial cell wall, which is located at the periphery of Gram-positive bacteria and within the periplasm of Gram-negative bacteria, comprises a glycopeptide polymer synthesized through cross-linking of glycans to peptide stems on alternating saccharides, which is known commonly as peptidoglycan.[A232920] Cell wall formation, recycling, and remodelling require numerous enzymes, including a family of enzymes with similar active site character despite distinct and sometimes overlapping roles as carboxypeptidases, endopeptidases, transpeptidases, and transglycosylases, known as "penicillin-binding proteins" (PBPs). The number of PBPs differs between bacteria, in which some are considered essential and others redundant. In general, inhibition of one or more essential PBPs results in impaired cell wall homeostasis, loss of cell integrity, and is ultimately bactericidal.[A232920][A232925][A232930]
Cefixime is a cephalosporin and cephalosporins work by using their beta-lactam rings to inhibit bacterial cell wall synthesis by binding to the penicillin-binding proteins transpeptidases on bacteria.[A262995][A262945][A262950] The inhibition of synthesis of the bacteria cell wall will cause lysis, particularly in fast growing organisms such as bacteria.[A262945] Specifically, cephalosporins inhibit penicillin-sensitive enzymes responsible for the final 3D structure of the bacterial cell wall which in turn inhibit bacterial cell wall peptidoglycan synthesis.[T894, T322]
Cefixime is a cephalosporin and cephalosporins work by using their beta-lactam rings to inhibit bacterial cell wall synthesis by binding to the penicillin-binding proteins transpeptidases on bacteria.[A262995][A262945][A262950] The inhibition of synthesis of the bacteria cell wall will cause lysis, particularly in fast growing organisms such as bacteria.[A262945] Specifically, cephalosporins inhibit penicillin-sensitive enzymes responsible for the final 3D structure of the bacterial cell wall which in turn inhibit bacterial cell wall peptidoglycan synthesis.[T894, T322]
Pharmacodynamics
Cefixime, a broad-spectrum antibiotic, is an orally-active third-generation semisynthetic cephalosporin.[A262894][L49293] Like other cephalosporins, the antibacterial action of cefixime results from inhibition of cell wall synthesis.[L49293] Also like other cephalosporins, cefixime is stable when in the presence of certain beta-lactamase enzymes, which means certain organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases could be susceptible to cefixime.[L49293]
Use of cefixime can result in hypersensitivity reactions including anaphylactic/anaphylactoid reactions and Clostridium difficile-associated diarrhea (CDAD); it may also be associated with a fall in prothrombin activity.[L49293] Cefixime doses should be adjusted for patients that have renal impairment and patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD), while patients on dialysis should be monitored while taking cefixime.[L49293]
Use of cefixime can result in hypersensitivity reactions including anaphylactic/anaphylactoid reactions and Clostridium difficile-associated diarrhea (CDAD); it may also be associated with a fall in prothrombin activity.[L49293] Cefixime doses should be adjusted for patients that have renal impairment and patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD), while patients on dialysis should be monitored while taking cefixime.[L49293]
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
With oral administration of cefixime, about 40%-50% is absorbed whether administered with or without food.
[L49293]
However, time to maximal absorption is increased approximately 0.8 hours when administered with food.
[L49293]
Cefixime administered as an single oral 200 mg tablet in healthy male volunteers had a corresponding Cmax of 3.25 mg/L and a corresponding Tmax of 4 hours.
[A263000]
Administration of cefixime as a 200 mg oral solution in healthy volunteers results in a Cmax of 3.22 micrograms/mL, while administration of 200 mg and 400 mg cefixime capsules results in a Cmax of 2.92 micrograms/mL and 4.84 micrograms/mL, respectively.
[A263005]
Administration of cefixime as a 200 mg intravenous solution, a 200 mg oral solution, a 200 mg capsule, and 400 mg capsule results in mean areas under the curve (AUC) of 47.0 μg.h/mL, 26.0 μg.h/mL, 23.6 μg.h/mL, and 39.4 μg.h/mL, respectively.
[A263005]
[L49293]
However, time to maximal absorption is increased approximately 0.8 hours when administered with food.
[L49293]
Cefixime administered as an single oral 200 mg tablet in healthy male volunteers had a corresponding Cmax of 3.25 mg/L and a corresponding Tmax of 4 hours.
[A263000]
Administration of cefixime as a 200 mg oral solution in healthy volunteers results in a Cmax of 3.22 micrograms/mL, while administration of 200 mg and 400 mg cefixime capsules results in a Cmax of 2.92 micrograms/mL and 4.84 micrograms/mL, respectively.
[A263005]
Administration of cefixime as a 200 mg intravenous solution, a 200 mg oral solution, a 200 mg capsule, and 400 mg capsule results in mean areas under the curve (AUC) of 47.0 μg.h/mL, 26.0 μg.h/mL, 23.6 μg.h/mL, and 39.4 μg.h/mL, respectively.
[A263005]
Half-life
Cefixime has a serum half-life averaging 3 to 4 hours in healthy subjects and is independent of dosage form.
[A262934][L49293]
It has ranged up to 9 hours in some normal volunteers.
[L49293]
In individuals with severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life of cefixime increased to an average of 11.5 hours.
[L49293]
[A262934][L49293]
It has ranged up to 9 hours in some normal volunteers.
[L49293]
In individuals with severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life of cefixime increased to an average of 11.5 hours.
[L49293]
Protein binding
Approximately 65% of cefixime is bound to serum protein, the serum protein binding is also concentration-independent.
[L49293]
[L49293]
Volume of distribution
Cefixime has a volume of distribution averaging 0.1 L/kg of body weight when administered orally.
[A262939]
[A262939]
Metabolism
There is no evidence of metabolism of cefixime in vivo.
[L49293]
[L49293]
Route of elimination
Approximately 50% of absorbed cefixime is excreted unchanged in the urine in 24 hours.
[L49293]
[L49293]
Clearance
Cefixime administered as an oral suspension with a dose of 8 mg/kg in children with urinary tract infections aged from 6 to 13 years resulted in a mean apparent total clearance rate of 4.74 ml/min/kg.
[A262980]
[A262980]
Transporters(4)
Proteins that transport this drug across cell membranes
Solute carrier family 15 member 1
SLC15A1
substrate
inhibitor
Specific functiondipeptide transmembrane transporter activity
Cellular location
Apical cell membrane
General function & pharmacology
Electrogenic proton-coupled amino-acid transporter that transports oligopeptides of 2 to 4 amino acids with a preference for dipeptides. Transports neutral and monovalently charged peptides with a proton to peptide stoichiometry of 1:1 or 2:1 (By similarity) .
PMID:15521010 PMID:18367661 PMID:19685173 PMID:26320580 PMID:7896779 PMID:8914574 PMID:9835627
Primarily responsible for the absorption of dietary di- and tripeptides from the small intestinal lumen (By similarity). Mediates transepithelial transport of muramyl and N-formylated bacterial dipeptides contributing to recognition of pathogenic bacteria by the mucosal immune system PMID:15521010 PMID:9835627
PMID:15521010 PMID:18367661 PMID:19685173 PMID:26320580 PMID:7896779 PMID:8914574 PMID:9835627
Primarily responsible for the absorption of dietary di- and tripeptides from the small intestinal lumen (By similarity). Mediates transepithelial transport of muramyl and N-formylated bacterial dipeptides contributing to recognition of pathogenic bacteria by the mucosal immune system PMID:15521010 PMID:9835627
Solute carrier family 22 member 7
SLC22A7
substrate
inhibitor
Specific functionalpha-ketoglutarate transmembrane transporter activity
Cellular location
Basolateral cell membrane
General function & pharmacology
Functions as a Na(+)-independent bidirectional multispecific transporter .
PMID:11327718 PMID:18216183 PMID:21446918 PMID:28945155
Contributes to the renal and hepatic elimination of endogenous organic compounds from the systemic circulation into the urine and bile, respectively .
PMID:11327718 PMID:25904762
Capable of transporting a wide range of purine and pyrimidine nucleobases, nucleosides and nucleotides, with cGMP, 2'deoxyguanosine and GMP being the preferred substrates .
PMID:11327718 PMID:18216183 PMID:26377792 PMID:28945155
Functions as a pH- and chloride-independent cGMP bidirectional facilitative transporter that can regulate both intracellular and extracellular levels of cGMP and may be involved in cGMP signaling pathways .
PMID:18216183 PMID:26377792
Mediates orotate/glutamate bidirectional exchange and most likely display a physiological role in hepatic release of glutamate into the blood .
PMID:21446918
Involved in renal secretion and possible reabsorption of creatinine .
PMID:25904762 PMID:28945155
Able to uptake prostaglandin E2 (PGE2) and may contribute to PGE2 renal excretion (Probable). Also transports alpha-ketoglutarate and urate .
PMID:11327718 PMID:26377792
Apart from the orotate/glutamate exchange, the counterions for the uptake of other SLC22A7/OAT2 substrates remain to be identified PMID:26377792
PMID:11327718 PMID:18216183 PMID:21446918 PMID:28945155
Contributes to the renal and hepatic elimination of endogenous organic compounds from the systemic circulation into the urine and bile, respectively .
PMID:11327718 PMID:25904762
Capable of transporting a wide range of purine and pyrimidine nucleobases, nucleosides and nucleotides, with cGMP, 2'deoxyguanosine and GMP being the preferred substrates .
PMID:11327718 PMID:18216183 PMID:26377792 PMID:28945155
Functions as a pH- and chloride-independent cGMP bidirectional facilitative transporter that can regulate both intracellular and extracellular levels of cGMP and may be involved in cGMP signaling pathways .
PMID:18216183 PMID:26377792
Mediates orotate/glutamate bidirectional exchange and most likely display a physiological role in hepatic release of glutamate into the blood .
PMID:21446918
Involved in renal secretion and possible reabsorption of creatinine .
PMID:25904762 PMID:28945155
Able to uptake prostaglandin E2 (PGE2) and may contribute to PGE2 renal excretion (Probable). Also transports alpha-ketoglutarate and urate .
PMID:11327718 PMID:26377792
Apart from the orotate/glutamate exchange, the counterions for the uptake of other SLC22A7/OAT2 substrates remain to be identified PMID:26377792
Organic anion transporter 3
SLC22A8
substrate
Specific functionorganic anion transmembrane transporter activity
Cellular location
Basolateral cell membrane
General function & pharmacology
Functions as an organic anion/dicarboxylate exchanger that couples organic anion uptake indirectly to the sodium gradient .
PMID:14586168 PMID:15644426 PMID:15846473 PMID:16455804 PMID:31553721
Transports organic anions such as estrone 3-sulfate (E1S) and urate in exchange for dicarboxylates such as glutarate or ketoglutarate (2-oxoglutarate) .
PMID:14586168 PMID:15846473 PMID:15864504 PMID:22108572 PMID:23832370
Plays an important role in the excretion of endogenous and exogenous organic anions, especially from the kidney and the brain .
PMID:11306713 PMID:14586168 PMID:15846473
E1S transport is pH- and chloride-dependent and may also involve E1S/cGMP exchange .
PMID:26377792
Responsible for the transport of prostaglandin E2 (PGE2) and prostaglandin F2(alpha) (PGF2(alpha)) in the basolateral side of the renal tubule .
PMID:11907186
Involved in the transport of neuroactive tryptophan metabolites kynurenate and xanthurenate .
PMID:22108572 PMID:23832370
Functions as a biopterin transporters involved in the uptake and the secretion of coenzymes tetrahydrobiopterin (BH4), dihydrobiopterin (BH2) and sepiapterin to urine, thereby determining baseline levels of blood biopterins .
PMID:28534121
May be involved in the basolateral transport of steviol, a metabolite of the popular sugar substitute stevioside .
PMID:15644426
May participate in the detoxification/ renal excretion of drugs and xenobiotics, such as the histamine H(2)-receptor antagonists fexofenadine and cimetidine, the antibiotic benzylpenicillin (PCG), the anionic herbicide 2,4-dichloro-phenoxyacetate (2,4-D), the diagnostic agent p-aminohippurate (PAH), the antiviral acyclovir (ACV), and the mycotoxin ochratoxin (OTA), by transporting these exogenous organic anions across the cell membrane in exchange for dicarboxylates such as 2-oxoglutarate .
PMID:11669456 PMID:15846473 PMID:16455804
Contributes to the renal uptake of potent uremic toxins (indoxyl sulfate (IS), indole acetate (IA), hippurate/N-benzoylglycine (HA) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF)), pravastatin, PCG, E1S and dehydroepiandrosterone sulfate (DHEAS), and is partly involved in the renal uptake of temocaprilat (an angiotensin-converting enzyme (ACE) inhibitor) .
PMID:14675047
May contribute to the release of cortisol in the adrenals .
PMID:15864504
Involved in one of the detoxification systems on the choroid plexus (CP), removes substrates such as E1S or taurocholate (TC), PCG, 2,4-D and PAH, from the cerebrospinal fluid (CSF) to the blood for eventual excretion in urine and bile (By similarity). Also contributes to the uptake of several other organic compounds such as the prostanoids prostaglandin E(2) and prostaglandin F(2-alpha), L-carnitine, and the therapeutic drugs allopurinol, 6-mercaptopurine (6-MP) and 5-fluorouracil (5-FU) (By similarity). Mediates the transport of PAH, PCG, and the statins pravastatin and pitavastatin, from the cerebrum into the blood circulation across the blood-brain barrier (BBB).
In summary, plays a role in the efflux of drugs and xenobiotics, helping reduce their undesired toxicological effects on the body (By similarity)
PMID:14586168 PMID:15644426 PMID:15846473 PMID:16455804 PMID:31553721
Transports organic anions such as estrone 3-sulfate (E1S) and urate in exchange for dicarboxylates such as glutarate or ketoglutarate (2-oxoglutarate) .
PMID:14586168 PMID:15846473 PMID:15864504 PMID:22108572 PMID:23832370
Plays an important role in the excretion of endogenous and exogenous organic anions, especially from the kidney and the brain .
PMID:11306713 PMID:14586168 PMID:15846473
E1S transport is pH- and chloride-dependent and may also involve E1S/cGMP exchange .
PMID:26377792
Responsible for the transport of prostaglandin E2 (PGE2) and prostaglandin F2(alpha) (PGF2(alpha)) in the basolateral side of the renal tubule .
PMID:11907186
Involved in the transport of neuroactive tryptophan metabolites kynurenate and xanthurenate .
PMID:22108572 PMID:23832370
Functions as a biopterin transporters involved in the uptake and the secretion of coenzymes tetrahydrobiopterin (BH4), dihydrobiopterin (BH2) and sepiapterin to urine, thereby determining baseline levels of blood biopterins .
PMID:28534121
May be involved in the basolateral transport of steviol, a metabolite of the popular sugar substitute stevioside .
PMID:15644426
May participate in the detoxification/ renal excretion of drugs and xenobiotics, such as the histamine H(2)-receptor antagonists fexofenadine and cimetidine, the antibiotic benzylpenicillin (PCG), the anionic herbicide 2,4-dichloro-phenoxyacetate (2,4-D), the diagnostic agent p-aminohippurate (PAH), the antiviral acyclovir (ACV), and the mycotoxin ochratoxin (OTA), by transporting these exogenous organic anions across the cell membrane in exchange for dicarboxylates such as 2-oxoglutarate .
PMID:11669456 PMID:15846473 PMID:16455804
Contributes to the renal uptake of potent uremic toxins (indoxyl sulfate (IS), indole acetate (IA), hippurate/N-benzoylglycine (HA) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF)), pravastatin, PCG, E1S and dehydroepiandrosterone sulfate (DHEAS), and is partly involved in the renal uptake of temocaprilat (an angiotensin-converting enzyme (ACE) inhibitor) .
PMID:14675047
May contribute to the release of cortisol in the adrenals .
PMID:15864504
Involved in one of the detoxification systems on the choroid plexus (CP), removes substrates such as E1S or taurocholate (TC), PCG, 2,4-D and PAH, from the cerebrospinal fluid (CSF) to the blood for eventual excretion in urine and bile (By similarity). Also contributes to the uptake of several other organic compounds such as the prostanoids prostaglandin E(2) and prostaglandin F(2-alpha), L-carnitine, and the therapeutic drugs allopurinol, 6-mercaptopurine (6-MP) and 5-fluorouracil (5-FU) (By similarity). Mediates the transport of PAH, PCG, and the statins pravastatin and pitavastatin, from the cerebrum into the blood circulation across the blood-brain barrier (BBB).
In summary, plays a role in the efflux of drugs and xenobiotics, helping reduce their undesired toxicological effects on the body (By similarity)
Solute carrier family 15 member 2
SLC15A2
inhibitor
Specific functiondipeptide transmembrane transporter activity
Cellular location
Apical cell membrane
General function & pharmacology
Proton-coupled amino-acid transporter that transports oligopeptides of 2 to 4 amino acids with a preference for dipeptides .
PMID:16434549 PMID:18367661 PMID:7756356
Transports neutral and anionic dipeptides with a proton to peptide stoichiometry of 2:1 or 3:1 (By similarity). In kidney, involved in the absorption of circulating di- and tripeptides from the glomerular filtrate .
PMID:7756356
Can also transport beta-lactam antibiotics, such as the aminocephalosporin cefadroxil, and other antiviral and anticancer drugs .
PMID:16434549
Transports the dipeptide-like aminopeptidase inhibitor bestatin (By similarity). Also able to transport carnosine .
PMID:31073693
Involved in innate immunity by promoting the detection of microbial pathogens by NOD-like receptors (NLRs) (By similarity).
Mediates transport of bacterial peptidoglycans across the plasma membrane or, in macrophages, the phagosome membrane: catalyzes the transport of certain bacterial peptidoglycans, such as muramyl dipeptide (MDP), the NOD2 ligand PMID:20406817
PMID:16434549 PMID:18367661 PMID:7756356
Transports neutral and anionic dipeptides with a proton to peptide stoichiometry of 2:1 or 3:1 (By similarity). In kidney, involved in the absorption of circulating di- and tripeptides from the glomerular filtrate .
PMID:7756356
Can also transport beta-lactam antibiotics, such as the aminocephalosporin cefadroxil, and other antiviral and anticancer drugs .
PMID:16434549
Transports the dipeptide-like aminopeptidase inhibitor bestatin (By similarity). Also able to transport carnosine .
PMID:31073693
Involved in innate immunity by promoting the detection of microbial pathogens by NOD-like receptors (NLRs) (By similarity).
Mediates transport of bacterial peptidoglycans across the plasma membrane or, in macrophages, the phagosome membrane: catalyzes the transport of certain bacterial peptidoglycans, such as muramyl dipeptide (MDP), the NOD2 ligand PMID:20406817
Scientific references(18)
McMillan A., Young H.
The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime.
International Journal of STD & AIDS
200718(4):253-254. doi: 10.1258/095646207780658971
Adam D., Hostalek U., Troster K.
5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: Comparison with 10-day penicillin V therapy.
Infection
199523(S2):S83-S86. doi: 10.1007/bf01742990
Leggett N.J., Caravaggio C., Rybak M.J.
Cefixime.
DICP
1990 May24(5):489-95. doi: 10.1177/106002809002400510
Barre J.
Cefixime.
Drugs
198938(4):524-550. doi: 10.2165/00003495-198938040-00004
Brittain D.C., Scully B.E., Hirose T., Neu H.C.
The pharmacokinetic and bactericidal characteristics of oral cefixime.
Clinical Pharmacology Therapeutics
1985 Nov38(5):590-4. doi: 10.1038/clpt.1985.229
Luo Y., Helmann J.D.
Analysis of the role of Bacillus subtilis sigma(M) in beta-lactam resistance reveals an essential role for c-di-AMP in peptidoglycan homeostasis.
Molecular Microbiology
2012 Feb83(3):623-39. doi: 10.1111/j.1365-2958.2011.07953.x. Epub 2012 Jan 4
Authors unspecified
Penicillins/cephalosporins/unspecified cephalosporins.
Reactions Weekly
20231987(1):201-201. doi: 10.1007/s40278-023-51945-6
Fisher J.F., Mobashery S.
Constructing and deconstructing the bacterial cell wall.
Protein Science
2020 Mar29(3):629-646. doi: 10.1002/pro.3737. Epub 2019 Nov 20
Bush K., Bradford P.A.
beta-Lactams and beta-Lactamase Inhibitors: An Overview.
Cold Spring Harb Perspect Medicine
2016 Aug 16(8). pii: cshperspect.a025247. doi: 10.1101/cshperspect.a025247
Sayed A.R.M., Shah N.R., Basso K.B., Kamat M., Jiao Y., Moya B., Sutaria D.S., Lang Y., Tao X., Liu W., Shin E., Zhou J., Werkman C., Louie A., Drusano G.L., Bulitta J.B.
First Penicillin-Binding Protein Occupancy Patterns for 15 beta-Lactams and beta-Lactamase Inhibitors in Mycobacterium abscessus.
Antimicrob Agents Chemother
2020 Dec 1665(1). pii: AAC.01956-20. doi: 10.1128/AAC.01956-20. Print 2020 Dec 16
Mamzoridi K., Kasteridou N., Peonides A., Niopas I.
Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose.
Pharmacology Toxicology
1996 Jun78(6):417-20. doi: 10.1111/j.1600-0773.1996.tb00229.x
Bui T, Preuss CV: Cephalosporins. .
Montay G., Le Liboux A., Thebault J.J., Roche G., Frydman A., Gaillot J.
Comparative Bioavailability Study of Cefixime Administered as Tablets or Aqueous Solution.
Drugs
199142(Supplement 4):6-9. doi: 10.2165/00003495-199100424-00004
Faulkner R.D., Fernandez P., Lawrence G., Sia L.L., Falkowski A.J., Weiss A.I., Yacobi A., Silber B.M.
Absolute bioavailability of cefixime in man.
Journal of Clinical Pharmacology
1988 Aug28(8):700-6. doi: 10.1002/j.1552-4604.1988.tb03203.x
Brogden R.N., Campoli-Richards D.M.
Cefixime.
A review of its antibacterial activity
Pharmacokinetic properties and therapeutic potential. Drugs. 1989 Oct38(4):524-50. doi: 10.2165/00003495-198938040-00004
Yang K.J., Kojima N., Bristow C.C., Klausner J.D.
Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis.
Sex Transm Diseases
2023 Mar 150(3):131-137. doi: 10.1097/OLQ.0000000000001742. Epub 2022 Dec 13
Adam D.
Overview of the clinical features of cefixime.
Chemotherapy
1998 Sep44 Suppl 1:1-5. doi: 10.1159/000048455
Arumugham V.B., Gujarathi R., Cascella M.
Third-generation Cephalosporins: an Appraisal.
InPharma
1984462(1):16-18. doi: 10.1007/bf03316175
ATC classification(3 codes)
ATC J01DD08
ATC J01RA16
ATC J01RA15
Affected organisms(1)
Enteric bacteria and other eubacteria
International brands(20)
Salt forms(1)
Cefixime trihydrate(DBSALT001818)
Experimental properties(2)
Protein Data Bank entries(1)
Commercial products(49)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cefixime
Additional database identifiers
Drugs Product Database (DPD)
1236
ChemSpider
4514923
BindingDB
84007
PDB
C04
ZINC
ZINC000004468778
GenBank Gene Database
X06479
UniProt Accession
DACA_ECOLI
GenBank Gene Database
X59460
GenBank Protein Database
41216
UniProt Accession
DACB_ECOLI
GenBank Gene Database
X06480
GenBank Protein Database
41218
UniProt Accession
DACC_ECOLI
GenBank Gene Database
X02164
GenBank Protein Database
581194
UniProt Accession
PBPA_ECOLI
GenBank Gene Database
X02163
GenBank Protein Database
42468
UniProt Accession
PBPB_ECOLI
GenBank Gene Database
K00137
UniProt Accession
FTSI_ECOLI
GenBank Gene Database
X04516
GenBank Protein Database
42314
UniProt Accession
MRDA_ECOLI
GenBank Gene Database
X04516
GenBank Protein Database
42314
UniProt Accession
MRDA_ECOLI
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10920
GenAtlas
SLC15A1
GeneCards
SLC15A1
GenBank Gene Database
U13173
GenBank Protein Database
773588
Guide to Pharmacology
984
UniProt Accession
S15A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10971
GeneCards
SLC22A7
GenBank Gene Database
AF097518
GenBank Protein Database
5001689
UniProt Accession
S22A7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10972
GeneCards
SLC22A8
GenBank Gene Database
AF097491
GenBank Protein Database
4378059
Guide to Pharmacology
1027
UniProt Accession
S22A8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10921
GenAtlas
SLC15A2
GeneCards
SLC15A2
GenBank Gene Database
S78203
GenBank Protein Database
999213
Guide to Pharmacology
985
UniProt Accession
S15A2_HUMAN
International reference pricing
3 formulations
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
From $0.45/ml
To $3.86/tablet
Suprax 20 mg/ml Suspension
$0.45/ml
Suprax 100 mg/5ml Suspension
$2.80/ml
Suprax 400 mg Tablet
$3.86/tablet
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
1 active patent
9233112
United States
Approved 12 Jan 2016 · Expires 14 Dec 2028
2y 8m
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 26 days ago(8 Mar 2026)